Please login to the form below

Not currently logged in

Merck & Co plays catch-up with osteoporosis data for odanacatib

Says study shows significant reduced risk of osteoporotic symptoms

Merck and Co - US headquarters Merck & Co has revealed positive results from a phase III fracture outcomes study for odanacatib in postmenopausal women with osteoporosis.

The company had intended to file the drug for approval in 2013 but put that plan on hold while it looked into a 'safety signal' of odanacatib.

Dr Keith Kaufman, vice president of clinical research for diabetes and endocrinology, said: “Merck believes the currently available data support a favourable benefit/risk profile for odanacatib.”

Among the adverse events checked during the trial were atrial fibrillation and major adverse cardiovascular events (MACE). Atrial fibrillation was reported in 92 patients in the odanacatib group and 80 patients in the placebo group; MACE were reported for 215 patients in the odanacatib group and 194 patients in the placebo group.

Merck said it would continue to collect data from the study and plans additional analyses of data from the trial including an independent re-adjudication of major adverse cardiovascular events, in support of regulatory submissions.

The study enrolled 16,713 women aged 65 years of age or older, diagnosed with osteoporosis, who have been postmenopausal for five years of more. Patients were randomised to receive 50mg of odanacatib or placebo per week.

In the long-term odanacatib fracture trial (LOFT), the cathespin inhibitor met its primary endpoints - significantly reduced the risk of osteoporotic hip, spine and non-vertebral fractures compared with a placebo.

Compared to patients receiving placebo, patients who received odanacatib had 72% relative risk reduction of clinical vertebral fractures and 54% relative risk reduction of new or worsening morphometric vertebral fractures.

The trial also found 47% relative risk reduction of clinical hip fractures and 23% relative risk reduction of clinical non-vertebral fractures.

Treatment with odanacatib also led to progressive increases in bone mineral density (BMD) over five years at the lumbar spine and total hip. Compared to the placebo, the change in BMD for lumbar spine was 11.2% and 9.5% for the total hip.

Article by
Kirstie Pickering

29th September 2014

From: Research



COVID-19 Updates and Daily News

Featured jobs


Add my company
3 Monkeys Zeno

3 Monkeys Zeno is an award winning global creative communications consultancy – home to a collective of creative and strategic...

Latest intelligence

How innovating study sites can improve patient recruitment efficiency
There are so many ways that clinical trials have innovated over the last few years. There is now a larger focus on making trials more patient-centric, more virtualised, and more...
Avoiding A Series of Unfortunate Events: launch lessons from lockdown
Chris Ross takes a novel look at launch excellence through the lens of COVID-19 and explores how pharma’s launch leaders are rewriting the story...
6 reasons patients drop out of clinical trials and 6 ways to fix it
If you’ve successfully recruited patients for your clinical trial, but one by one, they begin to drop out, then this information could be for you....